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Abstract One hundred and seventy 
patients with fluctuating Parkinson’s 
disease participated in an interna­
tional clinical trial to compare the ef­
fects of controlled-released Sinemet 
50/200 (mg carbidopa/mg levodopa; 
Sinemet CR) with standard Sinemet 
25/100 (Sinemet STD). The study 
design involved an 8-week open-la- 
bel titration (dose-finding) phase 
(STD and CR preparations given in­
dividually during weeks 1-4  and 5-8 
respectively) followed by a 24-week 
double-blind, double-dummy 
(placebo) treatment period. Drug ef­
ficacy was assessed using: (a) data 
from patients’ diaries (i.e. “on-off* 
periods) (b) the functional disability 
profile (Northwestern University 
Disability Scale), (c) the neurologi­
cal signs and symptoms (New York 
University Parkinson’s Disease 
Scale, NYUPDS), (d) global evalua­
tions made by the patient and treat­
ing physician and (e) the patient’s 
evaluation of sleep. The results indi­
cate that the number of “o f f ’ periods 
and the total NYUPDS score de­
creased significantly in the patients 
treated with Sinemet CR compared 
with those treated with Sinemet 
STD. Furthermore, the patient’s 
global evaluation was significantly 
better in the Sinemet CR group. The 
number of drug-related adverse ex­
periences was similar in the two 
groups, and only one serious event 
of this nature was reported.
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Introduction
Long-term treatment of Parkinson’s disease with lev­
odopa, in combination with a peripheral dopadecarboxy- 
lase inhibitor, is limited because responsiveness to lev­
odopa diminishes with time in most patients [12]. Pre­
dictable wearing-off periods and/or unpredictable “on- 
o f f ’ periods with random swings in motor functioning 
will occur frequently [3]. In treating the motor fluctua­
tions reported to be associated with certain pharmacoki­
netic and pharmacodynamic properties of oral levodopa 
[8, 15], continuous intravenous infusions of levodopa 
have proven helpful [15].
Controlled-release preparations of levodopa have been 
developed to induce a sustained elevation in plasma lev­
odopa concentrations. One such preparation of levodopa 
and carbidopa, Sinemet CR (50 mg carbidopa, 200 mg 
levodopa), has proven successful at ameliorating motor 
fluctuations [6, 17] and, importantly, has been shown to
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be safe and as well tolerated as conventional formulations 
[1, 2, 4, 5 ,7 , 9-11, 14, 16, 18, 19], The clinical efficacy of 
Sinemet CR has been found to be superior to that of the 
standard preparation of Sinemet (Sinemet STD; 25 mg 
carbidopa, 100 mg levodopa) in both open and double­
blind preliminary studies [1, 2, 4, 5, 7, 10, 11, 14, 16, 18,
19].
In this international multicentre clinical trial, the effi­
cacy and tolerability of Sinemet CR and Sinemet STD 
were compared in a large number of Parkinson’s disease 
patients who suffer motor fluctuations.
Patients and methods
Patients
Patients (n = 170) aged 35-75 years, presenting with Hoehn and 
Yahr stage II—IV Parkinson’s disease and demonstrating major 
clinical signs of the illness (e.g. rigidity, tremor, postural and/or 
gait disturbances and predictable deterioration in motor behaviour 
that fluctuated with levodopa treatment) were recruited from 16 
Dutch and 6 British neurological departments to participate in the 
trial. Of these 170 patients, 149 were assigned randomly to receive 
Sinemet STD (n -  75) or Sinemet CR (n = 74). A total of 131 pa­
tients completed the study, 68 in the Sinemet STD group and 63 
in the Sinemet CR group (see below, Safety and tolerability, for 
details concerning patients who discontinued the investigation). 
The use of concomitant anti-parkinsonism medication, including 
bromocriptine or selegiline, was permitted provided the dosage re­
mained stable throughout the study and during the 3 months im­
mediately preceding entry into the study. Patients taking permitted 
concomitant medication were randomized in such a way as to en­
sure equal distribution between the two treatment groups.
Study design
A complete physical examination and routine laboratory tests were 
performed before and after the study. The trial lasted 32 weeks and 
comprised two phases, an 8-week titration or optimal dose-finding 
phase followed by a 24-week double-blind phase,
During weeks 1--4 patients were titrated with Sinemet STD to 
achieve the optimal clinical response (i.e. determine the STD 
dosage that gave the best control of their Parkinsonian symptoms). 
During the next 4 weeks (i.e. weeks 5-8) the process was repeated 
using Sinemet CR.
Following the titration period, patients were randomized to 24 
weeks of double-blind treatment with either Sinemet STD plus 
placebo Sinemet CR or Sinemet CR plus placebo Sinemet STD. 
Treatment began with the optimal dose from the titration period, 
but investigators were allowed to alter (optimize) the dosage of 
Sinemet STD or CR (and placebo) at their own discretion during 
the double-blind phase.
Drug safety and efficacy determinations, unless specified, were 
performed every 2 weeks in the titration phase and at 4, 8, 12 and 
24 weeks into the double-blind period. Assessment of efficacy was 
based on the following measures: (a) data from the patient’s diary 
(questionnaire) concerning “on-off’ periods and dyskinesias (ab­
normal involuntary movements); (b) the functional disability pro­
file as assessed by the Northwestern University Disability Scale 
(NUDS; total score ranging from 0 to 50), to evaluate daily activi­
ties such as walking, dressing, eating, feeding, hygiene and speech; 
(c) the neurological signs and symptoms as evaluated through the 
New York University Parkinson’s Disease Scale (NYUPDS; five- 
point scale, 0-4), to determine clinical response in terms of rigid­
ity, tremor, bradykinesia, gait and postural stability; (d) the pa­
tient’s and physician’s global evaluations (five- or seven-point 
scales) of early morning akinesia, dystonia, pain and severity of 
disease; (e) the patient’s evaluation (four- to six-point scales) of 
sleep (the length of time it took to fall asleep, the number of limes 
they woke during the night, the rating of sleep, the average score 
for hours of sleep and the average time for the first morning pill to 
take effect). Measures b-e were determined at day 0 and following 
each titration phase and as stated above for the double-blind pe­
riod.
The number of doses per day and the daily dosage required for 
optimal control of motor fluctuations and other symptoms were 
recorded at the end of each dose-finding phase and at the end of 
the double-blind period.
Percentage changes, when computed, were calculated with re­
spect to the baseline value (end of titration with Sinemet STD).
Statistical methods
Wilcoxon’s signed rank test was applied to the patients’ diary data 
and to the NUDS and NYUPDS ratings to compare the pre-study 
data with the findings at the end of each dose-finding phase and at 
weeks 4, 8, 12 and 24 of the double-blind period.
Between-group comparisons during the double-blind period 
were made by analysis of variance (ANOVA) on the ranks of 
changes from baseline (end of the first titration period, i.e. week 
4), with treatment and stratum as model effects, for the following 
efficacy variables: number of “o ff ’ periods, number of hours of 
sleep, percentage of the waking day “on” and “off”, NUDS and 
NYUPDS scores, score for patient’s global evaluation, time for 
first morning pill to work, number of doses per day and total daily 
dosage. Between-group comparisons with baseline for physician’s 
global evaluation and the three remaining questions related to 
sleep (how long to fall asleep, how often awake during the night 
and rating of sleep) were made using McCullagh’s method [131-
The incidence of clinical and laboratory adverse experiences 
and vital signs was considered in the safety evaluation. The num­
ber of patients with adverse experiences during therapy was com­
pared between treatment groups using Fisher’s exact test.
All statistical comparisons were two-sided tests. Probability 
values were rounded off to two decimal places, and differences 
were considered statistically significant if the rounded probability 
value was < 0.05.
Results
Safety and tolerability
During the titration period with Sinemet STD 30 patients 
reported at least one adverse experience, of which 25 were 
considered to be at least possibly related to the study drug. 
During the double-blind treatment period with Sinemet 
STD, 15 patients had at least one adverse experience and 
12 of these adverse events were considered to be related 
to the test medication. During treatment with Sinemet CR, 
the number of patients with adverse experiences, 36 dur­
ing titration and 28 in the double-blind phase, was signif­
icantly higher (P < 0.05). Of the adverse experiences dur­
ing Sinemet CR treatment, 29 and 17 in the titration and 
the double-blind phase, respectively, were considered to 
be drug-related. The frequency of drug-related clinical ad­
verse effects did not differ significantly between the two 
treatments.
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There was only one serious drug-related clinical ad­
verse experience (increased dyskinesia during titration of 
Sinemet CR). A total of 12 patients withdrew during the 
titration periods because of clinical adverse experiences, 
two during titration with Sinemet STD and 10 during 
titration with Sinemet CR. During the double-blind period 
six patients withdrew because of clinical adverse experi­
ences: one in the Sinemet STD group and five in the 
Sinemet CR group. No significant difference was found 
between the groups with respect to the number of patients 
withdrawing during the titration or double-blind period 
due to drug-related adverse experiences.
Drug-related clinical adverse experiences were mainly 
related (80%) to the neuro-psychiatric and gastrointestinal 
systems. Dyskinesia, dystonia, headache, hallucinations 
and nausea and vomiting accounted for about half of the 
adverse experiences recorded.
Two patients in the Sinemet CR group were reported to 
have had an adverse experience based on laboratory re­
sults. One patient had a decreased plasma haemoglobin 
concentration and another had an elevated plasma platelet 
count, but neither event was considered to be drug-related.
During the study a total of 39 patients withdrew (21 
during the open-label titration and 18 during the double­
blind phase). Eighteen withdrawals were due to adverse 
effects, 9 to insufficient therapeutic response and 12 either 
to lack of compliance or through missing follow-up ap­
pointments.
Efficacy 
Titration phase
The mean proportion of the day during which the patient 
was asleep was 32% at the end of each titration period. 
The mean proportion of the waking day when the patient 
was “on” increased significantly (P < 0.01) from 68% at 
the end of the Sinemet STD titration period to 72% at the 
end of the Sinemet CR titration period (Fig. 1). Corre­
spondingly, the mean “o f f ’ time decreased from 32% to 
28% (P < 0.01). The mean number of “off” periods per 
day decreased significantly (P < 0.01) from four at the 
end of the Sinemet STD titration period to three at the end 
of the Sinemet CR titration period (Fig. 2).
The mean total NUDS score decreased significantly (P 
< 0.01): (a) from 10.7 in the pre-study assessment (STD 
0) to 10.2 at the end of the Sinemet STD titration period 
and (b) from 10.2 at the end of the Sinemet STD titration 
period to 9.7 at the end of the Sinemet CR titration period
(Fig. 3).
The mean total NYUPDS score also decreased signifi­
cantly (P < 0.01): from 8.0 at STD 0 to 7.0 at the end of 
the Sinemet STD titration period, and then again from 7.0 
to 6.3 at the end of the Sinemet CR titration period (Fig.
4).
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Fig. 1 Mean percentage of “on” time during open titration (n -  
131) with standard Sinemet 25/100 {STD; circles; day 0-week 4) 
and controlled-release Sinemet 50/200 (CR; squares; weeks 4—8) 
and during 24 weeks of double-blind treatment (DB) with Sinemet 
STD (n = 68) and Sinemet CR (n = 63). * P < 0.01 compared with 
STD-4 (baseline), ** P < 0.05 compared with STD-4, ++ Sinemet 
CR significantly different from Sinemet STD at same time in dou­
ble-blind period (P < 0.05)
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Fig. 2 Mean number of “off” periods during open titration (n -  
131) with Sinemet STD (circles; day 0-week 4) and Sinemet CR 
{squares; week 4-8) and during 24 weeks of double-blind treat­
ment with Sinemet STD (n = 68) and Sinemet CR 0? = 63). * P < 
0.01 compared with STD-4 (baseline), + Sinemet CR significantly 
different from Sinemet STD at same time in double-blind period
(P < 0.01)
The time needed to fall asleep, the number of “wake- 
ups” and the total time asleep did not change significantly 
during the two titration periods. However, the proportion 
of patients who rated their sleep as very good increased 
from 7% in the pre-study period to 11% at the end of the 
Sinemet STD titration period and to 15% at the end of the 
Sinemet CR titration period.
The mean time for the first morning pill to take effect 
increased from less than 30 min at the end of the Sinemet 
STD period to 30-60 min at the end of the Sinemet CR 
period.
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Fig. 3 Mean North-Western University Disability Scale score dur­
ing open titration (n = 131) with Sinemet STD (circles; day 
0-week 4) and Sinemet CR (squares; week 4-8) and during 24 
weeks of double-blind treatment with Sinemet STD (n = 68) and 
Sinemet CR (n = 63). # P < 0.01 compared with STD-0 (pre­
study), * P < 0.01 compared with STD-4 (baseline)
Titration period Double-blind period
Fig. 4 Mean New York University Parkinson’s Disease Scale 
score during open titration (/? = 1 3 1 )  with Sinemet STD (circles; 
day 0-week 4) and Sinemet CR (squares; week 4—8) and during 24 
weeks of double-blind treatment with Sinemet STD (n = 68) and 
Sinemet CR (n = 63). #  P < 0.01 compared with STD-0 (pre­
study), * P < 0.01 compared with STD-4 (baseline), ** P < 0.05 
compared with STD-4, ++ Sinemet CR significantly different from 
Sinemet STD at same time in double-blind period (P < 0.05)
The num ber o f doses per day at the end of the titration 
period with Sinem et C R  was approximately 70% of the 
doses recorded after Sinem et STD titration. However the 
Sinemet CR tablets contained twice the dosage of lev- 
odopa com pared with Sinem et STD tablets and hence the 
total daily levodopa dose at the end o f the Sinemet CR 
treatm ent was about 130% of the dose at the end of the 
Sinemet STD treatment.
Double-blind phase
As mentioned previously, “baseline” refers to the end of 
Sinemet STD titration (i.e. STD 4). At baseline, patient 
slept on average 32% of the day in both treatment groups. 
After 24 weeks of treatment small changes in proportion 
of the day spent sleeping were found in the two groups: 
—1% for Sinemet STD and +1% for Sinemet CR (n.s.). 
The mean proportion of the waking day when a patient 
was “on” averaged 68% at baseline and 64% after 24 
weeks of treatment in the Sinemet STD group (n.s.). In 
the Sinemet CR group the mean proportion of “on” time 
(68% at baseline) increased significantly to 73% at week 
4 (P < 0.05) and to 74% at week 8 (P < 0.01), but waned 
to 69% by the end of the study (see Fig. 1). A significant 
difference (P < 0.05) between the two treatments was re­
vealed during the double-blind period only at week 4, 
when percentage “on” time was significantly greater in 
the Sinemet CR group.
The mean daily number of “o f f ’ periods was four in 
both treatment groups at baseline. In the Sinemet STD 
group the mean number of “o f f ’ periods did not change 
significantly during the double-blind phase. However, in 
the Sinemet CR group a significant decrease (P < 0.01) of 
almost one “o f f ’ period was observed at all assessment 
times in the double-blind period (Fig. 2). Furthermore, 
there were significantly fewer “o f f ’ periods (P < 0 .0 1 ) in 
the Sinemet CR than in the Sinemet STD group at all as­
sessment times in the double-blind phase.
The mean baseline NUDS score was close to 10 in 
both treatment groups. During double-blind treatment nei­
ther the Sinemet STD nor the Sinemet CR group demon­
strated significant changes in NUDS score (Fig. 3).
For the mean total NYUPDS score a non-significant 
decreasing trend was seen during double-blind treatment 
in the Sinemet STD group, whereas a significant decrease 
(P < 0.01) of almost 1 was observed in the Sinemet CR 
group (Fig. 4). This reduction in NYUPDS score in the 
Sinemet CR group was mainly due to amelioration of 
rigidity, tremor and bradykinesia, not to improvement in 
gait and postural stability. Comparing the two medications 
in the double-blind period, the reduction in NYUPDS 
score with Sinemet CR was significantly greater (P < 
0.05) than that achieved with Sinemet STD after 6 
m onths’ treatment.
During the double-blind treatment period no signifi­
cant within- or between-group (treatment) changes were 
detected in the distribution of answers for any of the ques­
tions related to the evaluation of sleep. Baseline scores for 
hours of sleep, at approximately 4.5 (on a six-point scale), 
were equal in both groups (a score of 4 refers to 4 -6  h 
sleep, a score of 5, to 6-8  h sleep). Mean changes in the 
sleep score were small in both groups (on average an in­
crease of 0.2). The difference was significant (P < 0.05) at 
all evaluation times only in the Sinemet CR group. How-
4
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ever, the difference between treatments was not signifi­
cant at any time in the double-blind period.
The mean baseline score for time for the first pill to 
take effect was 2.0 in both groups (the scores ranged from
1 to 4, with 1 = < 30 min, 2 = 30-60 min, 3 = 60-90 min 
and 4 -  > 90 min). Mean changes were small in the 
Sinemet STD group but significant (P < 0.01) at each 
evaluation in the Sinemet CR group. Consequently, 
Sinemet CR took significantly more time to take effect 
than the Sinemet STD preparation throughout the double­
blind period. For example, the mean score at the end of 
the study was 2.6 in the Sinemet CR group versus 2.1 in 
the Sinemet STD patients (P < 0.01).
A score of 2 in the patient’s global evaluation implies 
that the patient feels better than at baseline, whereas a 
score of 3 implies that the patient feels the same as at 
baseline. In the Sinemet STD group, the mean score at 
week 24 was 3.1, while that in the Sinemet CR group was 
2.9. There was a significant difference in the patient’s 
global evaluation between the treatment groups in favour 
of Sinemet CR at weeks 12 (P < 0.05) and 24 (P < 0.05).
When considering the physician’s global evaluation, how­
ever, no significant difference between the two groups 
was found at any time.
In both treatment groups during the double-blind pe­
riod, there was a significant decrease in the mean number 
of doses per day relative to the end of titration with 
Sinemet STD. In the Sinemet STD group the number de­
creased from 5.7 to 5.1 (JP < 0.01), in the Sinemet CR 
group from 5.8 to 4.9 (P < 0.01).
Discussion
The principal findings in 131 patients with dose-related mo­
tor fluctuations in Parkinson’s disease were the following;
a) In both the open (titration) and double-blind phases, 
Sinemet CR, but not Sinemet STD, produced significant 
beneficial changes in the mean percentage “on” time and 
the number of “o f f ’ periods.
b) The number of “o f f ’ periods during the open and the 
double-blind phases was significantly lower with Sinemet 
CR than with Sinemet STD.
c) Sinemet CR tended to produce better NUDS scores than 
Sinemet STD and produced significantly better NYUPDS 
values.
d) The patient’s global evaluation was better with 
Sinemet CR than with Sinemet STD during the double­
blind treatment.
e) The safety and tolerability of Sinemet CR and Sinemet 
STD were similar.
The increased clinical efficacy, as measured with 
NYUPDS and NUDS, in the Sinemet CR patients implies 
that intracerebral dopamine concentrations were elevated
in these patients. However, this conclusion is untenable 
when taking into account the calculated bioavailability of 
levodopa in both groups. Although a 30% higher lev- 
odopa dosage was administered with Sinemet CR than 
with Sinemet STD, this higher Sinemet CR dosage re­
quired for control of parkinsonian symptoms is partly ac­
counted for by its lower bioavailability (71%) [19]. The 
calculated mean difference in daily levodopa dosage be­
tween Sinemet STD and Sinemet CR was only 80 mg. In­
complete absorption (incomplete disintegration of the 
polymer matrix), as well as increased first-pass decar­
boxylation due to slow drug release, may be responsible 
for the decreased bioavailability of Sinemet CR [19]. The 
higher efficacy may be attributable to the more stable lev­
odopa plasma concentrations.
Considered separately, the symptoms dealt with in the 
NYUPDS showed clinical improvement in the CR group, 
especially in the degree of rigidity and bradykinesia, but 
not in gait and postural instability. This pattern suggests 
the involvement of levodopa, which is known to amelio­
rate rigidity and bradykinesia rather than gait and postural 
stability. In previous work, plasma levodopa concentra­
tions in patients given Sinemet CR fluctuated less as a re­
sult of a lower plasma peak and a higher end-of-dose titre 
[6, 19]. The CR formulation thus ensures more “eco­
nomic” treatment by avoiding “o ff ’ periods induced by 
insufficient end-of-dose concentrations.
The number of doses per day in the Sinemet CR group 
decreased significantly, by 30% from 5.7 to 4.1, during 
the 4-week open titration period. Although the difference 
grew smaller during the 24-week double-blind period, the 
daily dose of Sinemet CR at the end of the study was still 
significantly lower (by 15%, 4.9 doses/day). Sinemet CR 
therapy, therefore, not only stabilizes plasma levodopa 
concentrations but also results in prolonged levodopa ac­
tivity, which is more practical and convenient for the pa­
tient.
The prolonged and stabilizing effects of Sinemet CR 
are also reflected by the “on” and “o ff ’ scores. Moreover, 
dystonia was found to be improved more in the CR than in 
the STD group (levodopa-induced dystonia generally oc­
curs as an end-of-dose phenomenon, and its amelioration 
should correspond to an increase in “on” time).
The improvement in clinical efficacy was not obtained 
at the expense of an increase in drug-related adverse ef­
fects in the participating patients; adverse events were 
seen equally in the Sinemet STD and Sinemet CR groups 
and consisted mainly of gastrointestinal and neuropsychi­
atric complaints.
Patients reported a delayed response to Sinemet CR 
compared with Sinemet STD. It was observed that pa­
tients who broke their CR tablets in half for the first morn­
ing dose seemed to suffer less from this problem. Increas­
ing the surface area by breaking the tablet may have pro­
moted faster dissolution and absorption, leading to an ear­
lier rise to peak plasma levodopa concentrations [11].
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Increase in dyskinesia during Sinemet CR treatment 
was noted in the m ore seriously affected patients, possibly 
due to their narrow er therapeutic window. The occurrence 
of dyskinesia appeared to depend on circumstances and 
disease factors rather than on the levodopa formulation. 
This is consistent with the findings o f  previous studies [6, 
16, 18].
This study demonstrated that Sinemet CR had greater 
clinically beneficial effects than Sinemet STD on “o f f ’ 
periods, NUDS score and patient’s global evaluation dur­
ing both the open-label titration phase and the 24-week 
double-blind treatment period. These benefits were not 
achieved at the expense of safety and/or tolerability, and the 
amount of total daily bioavailable levodopa was not greater.
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